Many patients achieved both clinically meaningful itch reduction and nodule clearance in PRIME and PRIME2
PRIME 18+ YEARS
≥4-POINT IMPROVEMENT IN
WI-NRS + IGA PN-S 0 OR 1 AT WEEK 24
(secondary endpoint)1-3
- A nominal difference was observed at Week 8 (12% with DUPIXENT vs 0% with placebo) and at Week 12 (20% with DUPIXENT vs 5% with placebo)3
PRIME2 (18+ YEARS)
- At Week 8 and Week 12, 8% and 17% of patients treated with DUPIXENT vs 5% and 9% with placebo, respectively, had improvement in both itch and nodule clearance. A significantly greater proportion of DUPIXENT patients achieved improvement in both itch and nodule clearance at Week 24 (32% with DUPIXENT vs 9% with placebo; P<0.001)1-3
Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME and PRIME2. Data were not multiplicity controlled.
Watch healthcare providers discuss results with DUPIXENT
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; WI-NRS, Worst Itch numerical rating scale.